Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome

Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome

Efficacy, tolerability and cardioprotective properties of rilmenidine were examined in patients with mild to moderate arterial hypertension (AH). The trial involved 51 hypertensive subjects, mean age 57,7+2,5 years. After wash-out period, rilmenidine was administered in the daily dose of 1-2 mg. At...

Descripció completa

Dades bibliogràfiques
Autors principals:	S. S. Yakushin, N. I. Ivankova, N. S. Sazonova, N. V. Vilesova, G. O. Ivanova
Format:	Article
Idioma:	Russian
Publicat:	«FIRMA «SILICEA» LLC 2004-12-01
Col·lecció:	Российский кардиологический журнал
Matèries:	arterial hypertension metabolic syndrome cardioprotective effects rilmenidine
Accés en línia:	https://russjcardiol.elpub.ru/jour/article/view/2326

Ítems similars

EFFECT OF ANTIHYPERTENSIVE THERAPY WITH RILMENIDINE ON COGNITIVE FUNCTION IN ELDERLY HYPERTENSIVE PATIENTS
per: S. V. Nedogoda, et al.
Publicat: (2016-01-01)

ASSESSMENT OF RILMENIDINE EFFICIENCY IN PATIENTS WITH ARTERIAL HYPERTENSION WITH DETERIORATION OF DAILY PROFILE OF BLOOD PRESSURE
per: P. P. Tikhonov, et al.
Publicat: (2015-12-01)

Perspectives of decreasing individual cardiovascular risk in high- and very high risk patients with arterial hypertension, treated with rilmenidine
per: S. V. Nedogoda, et al.
Publicat: (2005-06-01)

Workplace arterial hypertension: potential of rilmenidine-based combination therapy
per: S. I. Drozdetsky, et al.
Publicat: (1970-01-01)

Rilmenidine treatment in hypertensive patients with cerebrovascular transient ischemic attacks
per: A. P. Kondrakhin, et al.
Publicat: (2005-10-01)

Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity
per: E. V. Eliseeva, et al.
Publicat: (1970-01-01)

THE WAYS OF SYMPATHETIC SYSTEM OVERACTIVITY BLOCKING: RILMENIDINE VERSUS ATENOLOL
per: Y. R. Kasherininov, et al.
Publicat: (2016-01-01)

Autophagy and anti-inflammation ameliorate diabetic neuropathy with Rilmenidine
per: Mehmet Burak Yalçın, et al.
Publicat: (2023-12-01)

Rilmenidine Protects Against Joint Damage in MIA-induced Model of Osteoarthritis in Rats
per: Osman Kukula, et al.
Publicat: (2024-02-01)

Main results of the Russian trial «ALTAIR»
per: E. V. Shlyakhto, et al.
Publicat: (2006-02-01)

Comparison in conscious rabbits of the baroreceptor-heart rate reflex effects of chronic treatment with rilmenidine, moxonidine, and clonidine
per: Monique L Parkin, et al.
Publicat: (2016-11-01)

ARTERIAL HYPERTENSION IN YOUNG PEOPLE: EFFICACY OF SYMPATHOLYTIC THERAPY
per: N. N. Nikitina, et al.
Publicat: (2015-12-01)

Effects of centrally acting antihypertensive drugs on the microcirculation of spontaneously hypertensive rats
per: V. Estato, et al.
Publicat: (2004-10-01)

PHARMACEUTICAL CORRECTION OF VASCULAR DISTURBANCES IN PATIENTS WITH ARTERIAL HYPERTENSION
per: L. A. Khaisheva, et al.
Publicat: (2010-10-01)

Combined treatment of arterial hypertension: focus on calcium antagonist and ACE inhibitor combination
per: V. I. Makolkin
Publicat: (2008-12-01)

Not first‐line antihypertensive agents, but still effective—The efficacy and safety of imidazoline receptor agonists: A network meta‐analysis
per: András Érszegi, et al.
Publicat: (2024-06-01)

Cerebral blood flow and blood rheology in hypertensive patients during rilmenidine treatment
per: L. I. Markova, et al.
Publicat: (2004-06-01)

BISOPROLOL AND METFORMIN IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
per: V. A. Nevzorova, et al.
Publicat: (2015-12-01)

Prevalence of metabolic syndrome and its components in patients with arterial hypertension and obesity
per: I. E. Chazova, et al.
Publicat: (2005-12-01)

Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
per: I. N. Medvedev, et al.
Publicat: (2007-06-01)

Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
per: I. N. Medvedev, et al.
Publicat: (2008-10-01)

Eprosartan effects on intravascular platelet activity in patients with arterial hypertension and metabolic syndrome
per: I. N. Medvedev, et al.
Publicat: (2008-02-01)

Intravascular platelet activity correction by fosinopril in arterial hypertension patients with metabolic syndrome
per: I. N. Medvedev, et al.
Publicat: (2006-10-01)

Microcirculatory function in patients with arterial hypertension, metabolic syndrome and diabetes mellitus
per: A. P. Vasilyev, et al.
Publicat: (2008-10-01)

Some hormonal systems in males with arterial hypertension and metabolic syndrome
per: A. N. Britov, et al.
Publicat: (2006-06-01)

CORRECTION OF AGGREGATIVE FUNCTION OF THE TROMBOCYTES IN ARTERIAL HYPERTENSION PATIENTS WITH METABOLIC SYNDROM UNDER THE INFLUENCE OF SIMVASTATINE
per: N. J. Gromnazky, et al.
Publicat: (2003-12-01)

Metabolic syndrome in patients with arterial hypertension living in the Far North (on the example of the Khanty-Mansi Autonomous Okrug — Yugra)
per: E. G. Ivanova, et al.
Publicat: (2023-04-01)

The comorbid patients with arterial hypertension, chronic heart failure and chronic kidney disease: the role of fosinoprile
per: G. N. Gorokhovskaya, et al.
Publicat: (2018-04-01)

Arterial hypertension and metabolic syndrome: specifics of antihypertensive therapy
per: L. I. Abasova, et al.
Publicat: (2011-08-01)

Features of the clinical course of arterial hypertension in alien residents of Western Siberia with the establishment of patterns of metabolic changes
per: E. G. Ivanova, et al.
Publicat: (2022-07-01)

Spirapril effects on heart remodeling in patients with mild to moderate arterial hypertension
per: M. M. Beraya, et al.
Publicat: (2007-02-01)

Pathogenesis of arterial hypertension within the metabolic syndrome
per: A S Ryazanov, et al.
Publicat: (2003-03-01)

Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
per: M. M. Beraya, et al.
Publicat: (1970-01-01)

Imidazoline receptor agonist moxonidine and arterial hypertension treatment in women with menopausal metabolic syndrome
per: E. V. Tishina, et al.
Publicat: (2011-06-01)

Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome
per: V. V. Trusov, et al.
Publicat: (2007-08-01)

AFFECTIVE DISORDERS IN MEN WITH ARTERIAL HYPERTENSION IN COMBINATION WITH METABOLIC SYNDROME
per: Roman A. Yaskevich, et al.
Publicat: (2022-08-01)

AFFECTIVE DISORDERS IN WOMEN WITH ARTERIAL HYPERTENSION IN COMBINATION WITH METABOLIC SYNDROME
per: Roman A. Yaskevich, et al.
Publicat: (2022-06-01)

The efficacy of available supplements and medical drugs in longevity medicine - a review
per: Michał Łata, et al.
Publicat: (2025-01-01)

SHIFTWORK AS ONE OF RISK FACTORS OF ARTERIAL HYPERTENSION AND METABOLIC DISORDERS
per: I. S. Dzherieva, et al.
Publicat: (2015-12-01)

Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke
per: O. A. Osipova, et al.
Publicat: (2022-10-01)